Experts sound alarm as health conditions worsen across vulnerable region: 'Soon we will be seeing it as a public health emergency'
Scientists are warning of an upswing in heat-related and vector-borne illnesses in one Indian state due to rising global temperatures.
Increased humidity and soaring temperatures in the southern Indian state of Tamil Nadu are causing a surge in a disease carried by mites, along with a host of other health concerns, the Federal reported.
Heavy rains over the past few years have contributed to an upswing in cases of scrub typhus, the publication said, pointing to a recent study that found that for every 1% increase in mean relative humidity there was a 7.6% surge in scrub typhus cases. Meanwhile, an increase of one millimeter of rainfall contributed to 0.5-0.7% of monthly cases.
The publication also reported that the state recorded 26,740 cases of dengue in 2024 and 13 deaths — this was the highest number of cases in the last six years. Meanwhile, cases of a mosquito-borne illness called chikungunya rose from 153 in 2021 to 603 in 2024, and leptospirosis, a waterborne illness, is experiencing a gradual increase as well. Plus, extreme temperatures have led to a rise in heat stress and heat-related illnesses, along with mental health concerns.
"As the summer unfolds and the climate worsens, hospitals and healthcare providers across India must prepare for a climate-induced health crisis," Dr. Ilankumaran Kaliamoorthy, chief executive officer and senior consultant of liver anaesthesia and intensive care at Rela Hospital, told The Federal. "Without appropriate actions, these climate changes will continue to worsen, and soon we will be seeing it as a public health emergency instead of just an environmental issue."
Scrub typhus is a potentially life-threatening bacterial infection with no preventative vaccination available. Meanwhile, 21,000 dengue deaths are reported annually across the globe, according to the CDC. However, the agency reports that even milder cases of this mosquito-borne disease cause symptoms like severe headache, pain behind the eyes, muscle and joint pains, nausea, and vomiting.
Tamil Nadu isn't the only place experiencing a surge in vector-borne illnesses like dengue and scrub typhus. For instance, warmer temperatures and a variation in the length of dry seasons appear to be influencing the prevalence of dengue fever in the Philippines, according to one study.
Many vectors, such as mosquitoes, benefit from warmer temperatures and more humid conditions, which helps them to establish themselves in new geographical locations and lengthen their breeding seasons. For example, one study found that several mosquito species populations are set to expand their ranges in North and South America in the coming years, thanks to warmer temperatures.
The Cleveland Clinic says the best way for people to prevent typhus is by taking action to prevent getting bitten by disease-carrying mites. This includes wearing insect repellent and long sleeves, keeping rodents away from work, home, and play areas, and showering or bathing in warm water regularly.
Similarly, the CDC recommends insect repellent and long sleeves as two actions to help prevent mosquito-borne diseases like dengue.
Do you worry about the quality of the air inside your home?
Yes — often
Yes — but only sometimes
Only when it's bad outside
No — I never do
Click your choice to see results and speak your mind.
Meanwhile, some local communities are taking action to remove the culprits of these diseases. For example, officials in one Florida county are using X-rays to kill invasive mosquitoes there, and one Manila neighborhood has enacted a controversial "bounty" program that pays residents to collect mosquitoes.
Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
H5N1 bird flu ‘capable of airborne transmission'
H5N1 bird flu is capable of spreading through the air, a new animal study from the US Centres for Disease Control (CDC) has found. H5N1 was believed to spread primarily through direct contact with infected animals or their bodily fluids, but the new findings suggest it can also be transmitted through respiratory droplets and aerosol, raising concerns about its ability to cause a future pandemic. The study, published in Emerging Infectious Diseases, was based on a sample of H5N1 extracted from a dairy worker in Michigan who contracted the virus last year. The CDC scientists then used this sample to infect a group of ferrets, which are considered a 'gold standard' in flu research due to the similarity between their respiratory system and that of human. The infected animals were placed in close proximity to six other healthy ferrets and observed for three weeks. Within 21 days, three of the previously uninfected ferrets had contracted H5N1 – without any direct physical contact – indicating that the virus can travel through the air through a 'respiratory droplet transmission model'. The researchers also collected aerosol samples from the air surrounding the ferrets, and found infectious virus and viral RNA to be present, indicating that H5N1 can, like Covid-19, be transmitted through both respiratory droplets and aerosols – smaller particles that can travel longer distances and remain suspended in the air for extended periods. Respiratory droplets, on the other hand, are larger and do not travel as far in the air, requiring closer contact with an infected person for transmission. Since 2024, at least 70 people in the US have been infected with H5N1, the majority of them workers on poultry or dairy farms where the virus was present. Bird flu has spread to more than 1,000 dairy farms across the country over the past year and is now endemic among US cattle. 'This study is important as it provides yet more evidence that the H5N1 influenza virus that is circulating in dairy cattle in the USA is, in principle, capable of respiratory transmission,' Prof Ed Hutchinson, Professor of Molecular and Cellular Virology, MRC-University of Glasgow Centre for Virus Research told The Telegraph. '[The study] does this using experimental animals that experience and transmit influenza in similar ways to humans, so it warns us of what the virus could do in humans under the right circumstances,' Prof Hutchinson added. The study's authors warned that their findings underline the 'ongoing threat to public health' H5N1 poses, emphasising the need for 'continual surveillance and risk assessment… to prepare for the next influenza pandemic'. Most human cases reported in the US so far have resulted from direct physical contact with sick animals or their fluids, including cow's milk. But experts have warned that, as H5N1 continues to infect animal populations and 'jump' to humans, it is only a matter of time before the virus undergoes the mutations necessary to spread effectively from person to person. 'Because avian H5N1 viruses cross the species barrier and adapt to dairy cattle, each associated human infection presents further opportunity for mammal adaptation,' the study's authors said. Protect yourself and your family by learning more about Global Health Security Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.


CNBC
an hour ago
- CNBC
Field: Vaccine fatigue has caused flu vaccination rates to fall slightly
Emily Field, Barclays head of European pharma research, discusses RFK Jr.'s call to overhaul the CDC vaccine panel, vaccine skepticism, and the impact on stocks like Merck amid new RSV vaccine approvals.
Yahoo
an hour ago
- Yahoo
ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics
ST. PAUL, Minn., June 10, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Immuneel Therapeutics has been awarded a $150,000 G-Rex® Grant to support process development aimed at enhancing the scalability and cost-effectiveness of CAR-T cell manufacturing in India. "The blood cancer burden on India's population is substantial, around 120,000 new cases of lymphoma, leukemia, and multiple myeloma are diagnosed each year. Unfortunately, almost 70,000 Indians will die every year from these afflictions, devastating the lives of their families and communities. To afford access to all Indian patients in need, and to capitalize on the immense commercial potential of our pipeline, we need to think prudently and practically about our manufacturing approach. In the short term, our manufacturing demands are almost 200 drug products per day, and this may increase as CAR-T cell therapies move closer to front line treatment. The only practical way for us to industrialize our production and produce a supply of drug product commensurate with total patient demand is to transition to G-Rex," said Dr. Lakshmikanth Gandikota, Head of R&D, MSAT Intellectual Property, and Translational Research, at Immuneel Therapeutics Limited. "We are extremely impressed by the speed, resourcefulness, creativity, discipline, and entrepreneurialism of the team at Immuneel and are happy to see that India, as a whole, is making significant strides toward CAR-T availability. It gives us a great sense of satisfaction to be in a position to help bring hope to cancer patients in India, one G-Rex at a time," said John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex. As part of Immuneel's G-Rex Grant, they will perform process development, qualification, and validation of a G-Rex based CAR-T cell therapy production approach to dramatically increase the throughput capacity of their state-of-the-art, 12,000 square foot GMP facility. Located in Bengaluru and opened in 2021, Immuneel's Integrated Cell Therapy Development and Manufacturing Facility was the first of its kind in India and is designed to bring breakthrough cell and gene therapies to millions of patients in India. Lastly, Immuneel's G-Rex Grant will support the requisite comparability studies necessary to support a post-CAR-T approval manufacturing change from their difficult to scale low throughput all-in-one manufacturing equipment to a much simpler high throughput G-Rex centric approach. The high popularity of ScaleReady's G-Rex Grant Program led ScaleReady to increase award funds from the original amount of $20M to a total of $30M directed towards saving recipients significant time and money by expediting the path to optimized cell and gene-modified cell therapy manufacturing. Two hundred grants have already been awarded with over 50 new applications in the queue. Each G-Rex Grant recipient can obtain up to $300,000 and gain access to exclusive support from ScaleReady's growing consortium of G-Rex Grant Partners who bring best-in-class tools and technologies as well as unparalleled knowledge and expertise in the areas of cGMP manufacturing, quality and regulatory affairs, CGT business operations, and more. For more information about the G-Rex® Grant Program, please contact info@ About ScaleReadyScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing. The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 5 commercially approved CGT drugs. CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization. For more information about the ScaleReady G-Rex® Grant Program, please contact info@ About Wilson Wolf ManufacturingWilson Wolf ( is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production. Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time. About Bio-Techne CorporationBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. Contact: David Clair, Vice President, Investor Relations & Corporate About CellReady LLCCellReady is the world's first and only G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies. CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time. About Immuneel therapeutics Private LimitedImmuneel Therapeutics Private Limited is a cutting-edge biotechnology company based in Bangalore, India, at the forefront of advancing cell and gene therapies, as well as personalized immunotherapies, for cancer patients in India. As a research-driven and fully integrated organization, Immuneel is dedicated to making next-generation cancer treatments accessible and affordable, with a strong focus on innovation and clinical impact. The company's mission is to democratize advanced therapies by developing and commercializing breakthrough solutions tailored to the needs of Indian patients. As part of its growing portfolio, Immuneel has licensed and commercialized Qartemi® (varnimcabtagene autoleucel), a CD19 CAR-T cell therapy approved by India's Central Drugs Standard Control Organization (CDSCO) for the treatment of adult B-cell non-Hodgkin lymphoma a novel therapy for blood cancer, further demonstrating its commitment to transforming cancer care in India. Immuneel has a robust pipeline of CAR-T therapies for various indications in Oncology and AutoImmune diseases For more information, please visit: View original content to download multimedia: SOURCE Bio-Techne Corporation